MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Concert Pharmaceuticals Company Profile (NASDAQ:CNCE)

Consensus Ratings for Concert Pharmaceuticals (NASDAQ:CNCE) (?)
Ratings Breakdown: 5 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $27.20 (147.05% upside)

Analysts' Ratings History for Concert Pharmaceuticals (NASDAQ:CNCE)
Show:
DateFirmActionRatingPrice TargetActions
5/24/2016Brean CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$28.00 -> $24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2016JMP SecuritiesLower Price TargetMarket Outperform$28.00 -> $24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/26/2016AegisReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/8/2015Roth CapitalInitiated CoverageBuy$32.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/24/2015Ladenburg ThalmannBoost Price TargetBuy$24.00 -> $27.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/29/2014 forward)
Earnings History for Concert Pharmaceuticals (NASDAQ:CNCE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/3/2016        
5/5/2016Q116($0.45)($0.63)$1.24 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/1/2016Q415($0.05)$0.03$11.24 million$10.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.41)($0.39)$4.50 million$1.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2015Q215($0.46)$1.80$1.66 million$3.25 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2015Q115($0.38)($0.48)$2.70 million$1.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/27/2015Q414($0.60)($0.48)$1.38 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2014Q314($0.49)($0.43)$1.67 million$4.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2014Q214($0.42)($0.45)$1.30 million$1.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/14/2014Q114($0.49)($0.76)$0.44 million$1.61 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Concert Pharmaceuticals (NASDAQ:CNCE)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Concert Pharmaceuticals (NASDAQ:CNCE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Concert Pharmaceuticals (NASDAQ:CNCE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/12/2016Thomas G AuchinclossDirectorBuy2,000$10.11$20,220.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/11/2016Roger D TungCEOBuy19,610$10.55$206,885.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/16/2015Wilfred E JaegerDirectorSell10,360$19.57$202,745.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2015Wilfred E JaegerDirectorSell54,572$20.10$1,096,897.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/14/2015Pauline McgowanVPSell498$20.07$9,994.86View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/14/2015Wilfred E JaegerDirectorSell3,922$20.09$78,792.98View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/9/2015Ronald W. BarrettDirectorSell17,699$22.27$394,156.73View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2015Nancy StuartCOOSell23,216$24.29$563,916.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2015Robert SilvermanVPSell10,000$20.00$200,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2015Wilfred E JaegerDirectorSell120,000$18.22$2,186,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2015Wilfred E JaegerDirectorSell760,000$15.81$12,015,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2015Wilfred E JaegerDirectorSell92,215$16.75$1,544,601.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2015Wilfred E JaegerDirectorSell97,785$17.49$1,710,259.65View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2015Robert SilvermanVPSell5,000$16.35$81,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/11/2015Nancy StuartCOOSell46,430$15.00$696,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/11/2015Pauline McgowanVPSell5,973$16.00$95,568.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/10/2015Pauline McgowanVPSell22,122$13.90$307,495.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/18/2014Three Arch Management Iv, L.L.DirectorSell250,000$12.29$3,072,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/20/2014Skyline Venture Partners QualiMajor ShareholderBuy150,000$14.00$2,100,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/19/2014Life Science Ventures Vi G TvmDirectorBuy89,000$14.00$1,246,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/19/2014Plc GlaxosmithklineMajor ShareholderBuy35,000$14.00$490,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Concert Pharmaceuticals (NASDAQ:CNCE)
DateHeadline
06/28/16 03:17 PMShare Update and Earnings Review for Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) - Press Telegraph
06/28/16 03:17 PMA Look At Concert Pharmaceuticals - Seeking Alpha
06/24/16 03:25 PMConcert Pharmaceuticals, Inc. (NASDAQ:CNCE) Earnings Glance and Target Price Review - Engelwood Daily
06/24/16 07:02 AMConcert Pharmaceuticals Inc (CNCE) Updated Price Targets - FTSE News
06/24/16 07:02 AMCovering the Bases on Concert Pharmaceuticals, Inc. (NASDAQ:CNCE): Where is the Stock Going? - Press Telegraph
06/22/16 03:27 PMConcert Pharmaceuticals Inc (CNCE) Current Analyst Ratings - Fiscal Standard
06/10/16 03:13 PMCONCERT PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/10/16 11:21 AMConcert Pharma (CNCE) Announces Results from CTP-656 Phase 1 in CF; Superior PK Profile Noted - StreetInsider.com
06/10/16 09:49 AMConcert Pharmaceuticals Presents CTP-656 Phase 1 Results at European Cystic Fibrosis Conference - [at noodls] - Findings Confirmed Superior Pharmacokinetic Profile Relative to Kalydeco LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today presented results from a Phase 1 multiple ...
06/08/16 11:52 AMCONCERT PHARMACEUTICALS INC. (NASDAQ:CNCE) Financial Condition Compared to S&P 500 - CML News
06/06/16 06:43 AMConcert Pharmaceuticals Incorporated (NASDAQ:CNCE) Shorts Decreased by 12.56% After Short Covering - HNN
06/05/16 11:06 AMConcert Pharmaceuticals Inc (CNCE) Broker Price Targets For The Coming Week - Share Trading News
06/03/16 09:26 PMBvf INC Increased Concert Pharmaceuticals INC (NASDAQ:CNCE) by $6.80 Million as Shares Declined - CCH Daily News
06/03/16 03:27 PMConcert Pharmaceuticals, Inc. (NASDAQ:CNCE) Stock Update & Estimates - Stock Tick Tock
06/03/16 11:51 AMShare Rating Focus on Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) - HNN
06/02/16 11:28 AMTarget Price and Stock Performance Rundown for Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) - HNN - Target Price and Stock Performance Rundown for Concert Pharmaceuticals, Inc. (NASDAQ:CNCE)HNNDuring the latest trading session, Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) shares traded +2.10%. Monitoring the stock price relative to moving averages may offer enhanced perspective on stock performance. After a recent check, shares have been ...and more »
06/01/16 11:48 AMBroker Watchlist: Concert Pharmaceuticals Inc (CNCE) - Share Trading News - Broker Watchlist: Concert Pharmaceuticals Inc (CNCE)Share Trading News03/10/2014 – Wells Fargo began new coverage on Concert Pharmaceuticals Inc giving the company a “outperform” rating. The share price of Concert Pharmaceuticals Inc (CNCE) was down -0.82% during the last trading session, with a day high of 13.65.and more »
05/31/16 03:22 PMConcert Pharmaceuticals: Huge Value Hidden In This Microcap Gem - Seeking Alpha - Concert Pharmaceuticals: Huge Value Hidden In This Microcap GemSeeking AlphaA recently published article on Seeking Alpha did an excellent job of describing and analyzing Concert Pharmaceuticals' (NASDAQ:CNCE) intellectual property and drug pipeline. We will not reinvent the wheel in this article but rather attempt to inject ...
05/31/16 08:39 AMConcert Pharmaceuticals Inc (CNCE) Given “Buy” Rating at Brean Capital - Let Me Know About This - Concert Pharmaceuticals Inc (CNCE) Given “Buy” Rating at Brean CapitalLet Me Know About ThisConcert Pharmaceuticals Inc logo Brean Capital reaffirmed their buy rating on shares of Concert Pharmaceuticals Inc (NASDAQ:CNCE) in a research report released on Tuesday. In related news, CEO Roger D. Tung purchased 19,610 shares of the firm's ...and more »
05/27/16 06:51 PMHow Analysts Feel About Concert Pharmaceuticals Inc (NASDAQ:CNCE)? - Wall Street Hints and News - How Analysts Feel About Concert Pharmaceuticals Inc (NASDAQ:CNCE)?Wall Street Hints and NewsThis means NaN are positive. Concert Pharmaceuticals has been the topic of 8 analyst reports since August 12, 2015 according to StockzIntelligence Inc. Below is a list of Concert Pharmaceuticals Inc (NASDAQ:CNCE) latest ratings and price target changes.and more »
05/27/16 10:02 AMStock Rating Review for Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) - Wall Street Hints and News - Stock Rating Review for Concert Pharmaceuticals, Inc. (NASDAQ:CNCE)Wall Street Hints and NewsCovering equity analysts presently have a consensus stock rating of 1 on shares of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). Covering analysts will often provide Sell, Hold, or Buy recommendations based on their advanced research. This consensus ...and more »
05/26/16 07:28 AMTarget Check and Stock Performance Recap Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) - Wall Street Hints and News - Target Check and Stock Performance Recap Concert Pharmaceuticals, Inc. (NASDAQ:CNCE)Wall Street Hints and NewsTracking stock performance from various views may help with share evaluation. Some investors might be more focused on short-term share action while others may prefer to view long-term performance. In recent session activity, Concert Pharmaceuticals, Inc.and more »
05/20/16 10:26 AMAnalyst Rating Check on Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) - Wall Street Hints and News - Analyst Rating Check on Concert Pharmaceuticals, Inc. (NASDAQ:CNCE)Wall Street Hints and NewsCurrently, sell-side analysts have provided a consensus stock rating of 1 on shares of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). Analysts that cover the company will usually offer Buy, Sell, or Hold recommendations based on in-depth research.and more »
05/19/16 11:48 PMShare Performance and Target Price Review for Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) - Wall Street Hints and News - Share Performance and Target Price Review for Concert Pharmaceuticals, Inc. (NASDAQ:CNCE)Wall Street Hints and NewsLooking at stock activity from multiple angles may be of benefit when examining share performance. Investors have the ability to focus in on short or long term share performance. During the most recent trading session, Concert Pharmaceuticals, Inc.and more »
05/19/16 06:36 PMRevenue Update on Concert Pharmaceuticals Inc(NASDAQ:CNCE) - Trade Calls - Revenue Update on Concert Pharmaceuticals Inc(NASDAQ:CNCE)Trade CallsConcert Pharmaceuticals Inc(NASDAQ:CNCE) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during Pre-market on May 5, 2016. Company reported revenue of $56.00K. Analysts estimated a revenue of $1.24M. Earnings ...Concert Pharma (CNCE) Commences CTP-543 Phase 1StreetInsider.comConcert Pharmaceuticals Initiates Phase 1 Hair-Loss Drug Trial (NASDAQ:CNCE)Sonoran Weekly ReviewConcert Pharmaceuticals Inc (CNCE) - Broker UpdateRisers & Fallersall 5 news articles »
05/19/16 06:22 AMConcert Pharmaceuticals Initiates Phase 1 Trial of CTP-543 as a New Treatment for Alopecia Areata - [at noodls] - LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated its Phase 1 clinical program for CTP-543, which is being developed for the treatment ...
05/18/16 06:36 PMBroker Outlook For Concert Pharmaceuticals Inc (CNCE) - Share Trading News - Broker Outlook For Concert Pharmaceuticals Inc (CNCE)Share Trading NewsBroker Outlook For Concert Pharmaceuticals Inc (CNCE). By Brenton Akerman / in US Broker Ratings / on Wednesday, 18 May 2016 11:25 AM / 0 Comments. The most recently updated broker views and price targets issued for Concert Pharmaceuticals Inc ...
05/17/16 07:42 AMConcert Pharmaceuticals to Present at Several Upcoming Investor Conferences - [at noodls] - LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the following upcoming investor conferences: The UBS 2016 Global ...
05/14/16 11:31 PMConcert Pharmaceuticals, Inc. (NASDAQ:CNCE) Basic Consolidated EPS At $1.1429 - RealistInvestor.com - Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Basic Consolidated EPS At $1.1429RealistInvestor.comThe yearly basic consolidated EPS for Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) for the period ended 2015-12-31 was $1.1429. For the quarter ended 2015-12-31 the basic consolidated EPS was $1.1429. Earnings per share is the portion of the firm's ...
05/13/16 06:53 PMConsensus Rating Review for Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) - Wall Street Hints and News - Consensus Rating Review for Concert Pharmaceuticals, Inc. (NASDAQ:CNCE)Wall Street Hints and NewsEquity research analysts currently have a consensus rating of 1 on shares of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate into a Buy ...and more »
05/13/16 12:04 PMCONCERT PHARMACEUTICALS, INC. Financials -
05/13/16 09:00 AMNoteworthy Insider Buying and Selling at MiMedx Group, Aetna & Others -
05/11/16 07:02 PMConcert Pharmaceuticals: Investors Ignoring A New Blockbuster - Seeking Alpha - Seeking AlphaConcert Pharmaceuticals: Investors Ignoring A New BlockbusterSeeking AlphaConcert Pharmaceuticals (NASDAQ:CNCE) gave an update on their business on the recent earnings call this past Thursday, May 5th. What transpired was a tumultuous ride for the stock from ~$13.50/share to $10.67 at the close on May 10th. What happened ...
05/11/16 10:28 AMConcert Pharmaceuticals, Inc. :CNCE-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/09/16 12:23 AMNext Weeks Broker Price Targets For Concert Pharmaceuticals Inc (CNCE) - Share Trading News - Next Weeks Broker Price Targets For Concert Pharmaceuticals Inc (CNCE)Share Trading NewsConcert Pharmaceuticals Inc has a 50 day moving average of 13.63 and a 200 day moving average of 17.03. The stock's market capitalization is 239.60M, it has a 52-week low of 10.75 and a 52-week high of 25.04. The share price of the company (CNCE) ...and more »
05/07/16 11:30 PMAre Analysts Bearish Concert Pharmaceuticals Inc (NASDAQ:CNCE) After Last Week? - B.O.D.Y Confidential - Are Analysts Bearish Concert Pharmaceuticals Inc (NASDAQ:CNCE) After Last Week?B.O.D.Y ConfidentialThis means NaN are positive. Concert Pharmaceuticals has been the topic of 8 analyst reports since August 12, 2015 according to StockzIntelligence Inc. Below is a list of Concert Pharmaceuticals Inc (NASDAQ:CNCE) latest ratings and price target changes.and more »
05/06/16 06:55 PMAverage Analyst Rating for Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) - B.O.D.Y Confidential - Average Analyst Rating for Concert Pharmaceuticals, Inc. (NASDAQ:CNCE)B.O.D.Y ConfidentialWall Street analysts have provided an average broker recommendation of 1 on Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) shares. The rating is determined by using the average of all analyst recommendations taken into consideration by Zacks ...and more »
05/06/16 06:55 PMConcert Pharmaceuticals Becomes Oversold (CNCE) - A stock is considered to be oversold if the RSI reading falls below 30. In trading on Friday, shares of Concert Pharmaceuticals Inc (CNCE) entered into oversold territory, hitting an RSI reading of 28.4, after changing hands as low as $10.75 per share.
05/05/16 07:13 PMConcert Pharmaceuticals : reports 1Q loss - LEXINGTON, Mass. (AP) _ Concert Pharmaceuticals Inc. (CNCE) on Thursday reported a loss of $13.9 million in its first quarter. The Lexington, Massachusetts-based company said it had a loss of 63 cents per share. The biopharmaceutical company posted revenue ...
05/05/16 06:32 AMConcert reports 1Q loss -
05/05/16 06:11 AMConcert Pharmaceuticals Reports First Quarter 2016 Financial Results - [at noodls] - Conference Call Scheduled Today at 8:30 a.m. EDT LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the first quarter of 2016. ... This ...
05/05/16 06:07 AMQ1 2016 Concert Pharmaceuticals Inc Earnings Release - Before Market Open -
05/04/16 03:31 PMConcert Pharmaceuticals Unveils CTP-543 for Treatment of Alopecia Areata - [at noodls] - Phase 1 to Begin Second Quarter of 2016 Conference Call Scheduled Tomorrow at 8:30 a.m. EDT for Company Update and First Quarter 2016 Financial Results LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, ...
05/02/16 07:27 PMBroker Outlook For The Week Ahead: Concert Pharmaceuticals Inc (CNCE) - Share Trading News - Broker Outlook For The Week Ahead: Concert Pharmaceuticals Inc (CNCE)Share Trading News03/10/2014 – Wells Fargo began new coverage on Concert Pharmaceuticals Inc giving the company a “outperform” rating. The share price of Concert Pharmaceuticals Inc (CNCE) was down -2.59% during the last trading session, with a day high of 14.43.and more »
04/29/16 06:59 PMCommit To Purchase Concert Pharmaceuticals At $12.50, Earn 26.7% Annualized Using Options - Investors considering a purchase of Concert Pharmaceuticals Inc (CNCE) stock, but tentative about paying the going market price of $13.96/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting ...
04/28/16 03:15 PMConcert Pharmaceuticals Announces Positive Data from Multiple Dose Phase 1 Clinical Trial of CTP-656, Lead Candidate for the Treatment of Cystic Fibrosis - [at noodls] - Multiple Dose Data Continues to Support Once-Daily Dosing and Differentiated Metabolite Profile Data to be Presented at the European Cystic Fibrosis Conference in June 2016 LEXINGTON, Mass.--(BUSINESS ...
04/28/16 03:04 PM4:04 pm Concert Pharmaceuticals announces 'positive' topline data from a Phase 1 multiple ascending dose clinical trial of CTP-656 -
04/28/16 06:22 AMConcert Pharmaceuticals to Report First Quarter 2016 Financial Results on May 5, 2016 - [at noodls] - LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its first quarter 2016 financial results on Thursday, May 5, 2016, before the U.S. financial ...
04/27/16 07:07 PMConcert Pharmaceuticals, Inc. (NASDAQ:CNCE) Share Rating Recap - The Post - Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Share Rating RecapThe PostShares of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) are tracked by analysts as well as crowd investors. Research from Beta Systems keeps track of crowd sourced sentiment and provides consensus stock ratings. The rating information comes mainly ...and more »
04/27/16 07:07 PMConcert Pharmaceuticals, Inc. (NASDAQ:CNCE) Analyst Rating Review - The Post - Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Analyst Rating ReviewThe PostCovering analysts typically give Buy, Sell and Hold recommendations along with guidance and company earnings projections. Currently, there are 4 analysts that have provided ratings for Concert Pharmaceuticals, Inc. (NASDAQ:CNCE). 4 have rated the ...and more »
About Concert Pharmaceuticals

Concert Pharmaceuticals logoConcert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others segment. It has clinical candidates under development, including AVP-786, CTP-656, CTP-730 and JZP-386. The Company's deuterated chemical entity platform (DCE Platform) enables it to identify compounds for deuteration and to design, evaluate, develop and manufacture deuterated compounds. The Company is utilizing its DCE Platform to discover and develop product candidates for a range of indications. The Company's product candidate, CTP-656, is a next generation potentiator that the Company is initially developing for the treatment of cystic fibrosis in patients having gating mutations, including the G551D mutation. AVP-786 is a combination of a deuterated dextromethorphan analog and a low dose of quinidine.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CNCE
  • CUSIP:
Key Metrics:
  • Previous Close: $11.01
  • 50 Day Moving Average: $12.10
  • 200 Day Moving Average: $14.25
  • P/E Ratio: 13.22
  • P/E Growth: 0.00
  • Market Cap: $244.60M
  • Current Quarter EPS Consensus Estimate: $-2.58 EPS
Additional Links:
Concert Pharmaceuticals (NASDAQ:CNCE) Chart for Wednesday, June, 29, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha